 Immediate versus beta-blockade following thrombolytic therapy patients acute myocardial infarction Results Thrombolysis Myocardial Infarction TIMI II-B Study Thrombolysis Myocardial Infarction TIMI Phase II trial patients intravenous recombinant tissue-type plasminogen activator rt-PA conservative invasive strategy study effects immediate versus beta-blocker therapy patients eligible beta-blocker therapy group patients immediate intravenous group group immediate intravenous group hours rt-PA metoprolol mg intervals minutes total intravenous dose mg mg hours first hours mg hours patients group mg day mg day therapy groups primary end point global ejection fraction hospital discharge identical groups regional ventricular function similar groups Overall difference mortality immediate intravenous deferred groups subgroup low risk deaths weeks immediate beta-blocker therapy contrast deaths beta-blocker therapy findings secondary end point subgroup sufficient recommendation clinical use incidence reinfarction recurrent chest pain days immediate intravenous group appropriate postinfarction patients beta-blockers safe thrombolytic therapy decreased myocardial ischemia reinfarction first week benefit late administration ventricular function mortality